Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Ian E KropSeock-Ah ImCarlos Henrique BarriosHervé R BonnefoiJulie R GralowMasakazu ToiPaul A EllisLuca GianniSandra M SwainYoung-Hyuck ImMichelino De LaurentiisZbigniew NoweckiChiun-Sheng HuangLouis FehrenbacherYoshinori ItoJigna ShahThomas BouletHaiying LiuHarrison MachariaPeter TraskChunyan SongEric P WinerNadia HarbeckPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- phase iii
- metastatic breast cancer
- early breast cancer
- advanced non small cell lung cancer
- open label
- endothelial cells
- clinical trial
- healthcare
- palliative care
- phase ii
- quality improvement
- double blind
- positive breast cancer
- pluripotent stem cells
- placebo controlled
- radiation therapy